Platinum Drug Resistance in the Treatment of Lung Cancer Patients

Abstract

As a typical example of highly prevalent cancers worldwide, lung cancer poses a serious threat to human health. Therefore, this disease has various kinds of treatments. Among them, the treatment with platinumbased drugs has been greatly restricted due to the drug resistance. This problem poses a threat to the modern cancer medical system. In recent years, researchers have made great efforts to solve this difficult problem. Research on platinum-based drug resistance has achieved certain results. In clinical practice, some lung cancer patients have received effective treatment. This article analyzes the research on drug resistance, why lung cancer cells can produce drug resistance during the treatment process. The research was conducted from the aspects of the mechanism of action of platinum-based medicines, the expression of genes in lung cancer patients, the dysregulation of microRNAs, and epigenetics. Through various experimental studies, methods for improving the responsiveness of lung cancer cells to related medications have been obtained. For example, combined drug therapy, inhibition of gene expression, assisted treatment with nanotechnology, and combined with other therapies such as immunotherapy. The research can enhance the cure rate of lung cancer patients and provide a new approach for the effective treatment of lung cancer. However, at present, this problem still requires more innovative approaches to make lung cancer cells respond to related medications, so as to provide more options for cancer patients. In the future, in clinical research, modern technological methods can be combined with drugs to enhance the effect of platinumbased medications on lung cancer patients.